Mutations and prognosis in primary myelofibrosis von Vannucchi, A M, Lasho, T L, Guglielmelli, P, Biamonte, F, Pardanani, A, Pereira, A, Finke, C, Score, J, Gangat, N, Mannarelli, C, Ketterling, R P, Rotunno, G, Knudson, R A, Susini, M C, Laborde, R R, Spolverini, A, Pancrazzi, A, Pieri, L, Manfredini, R, Tagliafico, E, Zini, R, Jones, A, Zoi, K, Reiter, A, Duncombe, A, Pietra, D, Rumi, E, Cervantes, F, Barosi, G, Cazzola, M, Cross, N C P, Tefferi, A

Volltext

Differential clinical effects of different mutation subtypes in CALR-mutant myeloproliferative neoplasms von Pietra, D, Rumi, E, Ferretti, V V, Buduo, C A Di, Milanesi, C, Cavalloni, C, Sant'Antonio, E, Abbonante, V, Moccia, F, Casetti, I C, Bellini, M, Renna, M C, Roncoroni, E, Fugazza, E, Astori, C, Boveri, E, Rosti, V, Barosi, G, Balduini, A, Cazzola, M

Volltext

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients von Guglielmelli, P, Lasho, T L, Rotunno, G, Score, J, Mannarelli, C, Pancrazzi, A, Biamonte, F, Pardanani, A, Zoi, K, Reiter, A, Duncombe, A, Fanelli, T, Pietra, D, Rumi, E, Finke, C, Gangat, N, Ketterling, R P, Knudson, R A, Hanson, C A, Bosi, A, Pereira, A, Manfredini, R, Cervantes, F, Barosi, G, Cazzola, M, Cross, N C P, Vannucchi, A M, Tefferi, A

Volltext

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders von Cervantes, F, Passamonti, F, Barosi, G

Volltext

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group von Kröger, N M, Deeg, J H, Olavarria, E, Niederwieser, D, Bacigalupo, A, Barbui, T, Rambaldi, A, Mesa, R, Tefferi, A, Griesshammer, M, Gupta, V, Harrison, C, Alchalby, H, Vannucchi, A M, Cervantes, F, Robin, M, Ditschkowski, M, Fauble, V, McLornan, D, Ballen, K, Popat, U R, Passamonti, F, Rondelli, D, Barosi, G

Volltext

Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both von Koschmieder, S, Mughal, T I, Hasselbalch, H C, Barosi, G, Valent, P, Kiladjian, J-J, Jeryczynski, G, Gisslinger, H, Jutzi, J S, Pahl, H L, Hehlmann, R, Maria Vannucchi, A, Cervantes, F, Silver, R T, Barbui, T

Volltext

Rapid and long-lasting decrease of T-regulatory cells in patients with myelofibrosis treated with ruxolitinib von Massa, M, Rosti, V, Campanelli, R, Fois, G, Barosi, G

Volltext

Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelo... von Barosi, G, Mesa, R A, Thiele, J, Cervantes, F, Campbell, P J, Verstovsek, S, Dupriez, B, Levine, R L, Passamonti, F, Gotlib, J, Reilly, J T, Vannucchi, A M, Hanson, C A, Solberg, L A, Orazi, A, Tefferi, A

Volltext

Consensus-based definition of unfitness to intensive and non-intensive chemotherapy in acute myeloid leukemia: a project of SIE, SIES and GITMO group on a new tool for therapy deci... von Ferrara, F, Barosi, G, Venditti, A, Angelucci, E, Gobbi, M, Pane, F, Tosi, P, Zinzani, P, Tura, S

Volltext

Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3 von BARBUI, Tiziano, CAROBBIO, Alessandra, OTTOMANO, Cosimo, MARCHIOLI, Roberto, CUCCOVILLO, Ivan, BOTTAZZI, Barbara, MANTOVANI, Alberto, RAMBAIDI, Alessandro, FINAZZI, Guido, VANNUCCHI, Alessandro M, BAROSI, Giovanni, ANTONIOLI, Elisabetta, GUGLIELMELLI, Paola, PANCRAZZI, Alessandro, SALMOIRAGHI, Silvia, ZILIO, Pio

Volltext

JAK2(V617F) allele burden ⩾50% is associated with response to ruxolitinib in persons with MPN-associated myelofibrosis and splenomegaly requiring therapy von Barosi, G, Klersy, C, Villani, L, Bonetti, E, Catarsi, P, Poletto, V, Campanelli, R, Impera, S, Latagliata, R, Viarengo, G, Carolei, A, Massa, M, Musso, M, Crescimanno, A, Gale, R P, Rosti, V

Volltext

A randomized study of pomalidomide vs placebo in persons with myeloproliferative neoplasm-associated myelofibrosis and RBC-transfusion dependence von Tefferi, A, Al-Ali, H K, Barosi, G, Devos, T, Gisslinger, H, Jiang, Q, Kiladjian, J-J, Mesa, R, Passamonti, F, Ribrag, V, Schiller, G, Vannucchi, A M, Zhou, D, Reiser, D, Zhong, J, Gale, R P

Volltext

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations von Marchetti, M, Barosi, G, Cervantes, F, Birgegård, G, Griesshammer, M, Harrison, C, Hehlmann, R, Kiladjian, J-J, Kröger, N, McMullin, M F, Passamonti, F, Vannucchi, A, Barbui, T

Volltext

How can we know if new drugs are effective in myeloproliferative neoplasm-associated myelofibrosis? von Barosi, G, Gale, R P

Volltext

Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups von Onida, Francesco, Barosi, Giovanni, Leone, Giuseppe, Malcovati, Luca, Morra, Enrica, Santini, Valeria, Specchia, Giorgina, Tura, Sante

Volltext

Elevated C-reactive protein is associated with shortened leukemia-free survival in patients with myelofibrosis von Barbui, T, Carobbio, A, Finazzi, G, Guglielmelli, P, Salmoiraghi, S, Rosti, V, Rambaldi, A, Vannucchi, A M, Barosi, G

Volltext

Strategies for dissemination and implementation of guidelines von Barosi, G

Volltext

CALR mutation, MPL mutation and triple negativity identify patients with the lowest vascular risk in primary myelofibrosis von Finazzi, M C, Carobbio, A, Cervantes, F, Isola, I M, Vannucchi, A M, Guglielmelli, P, Rambaldi, A, Finazzi, G, Barosi, G, Barbui, T

Volltext

Reply to Passamonti et al: ruxolitinib and survival improvement in patients with myelofibrosis von Barosi, G, Gale, R P

Volltext

Does ruxolitinib improve survival of persons with MPN-associated myelofibrosis? Should it? von Barosi, G, Zhang, M-J, Gale, R Peter

Volltext